Exhibit 99.01

April 2017

Safe Harbor Statement Although we believe that we have a reasonable basis for each forward - looking statement contained in this presentation, we caution you that forward - looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward - looking statements contained in this presentation as a result of, among other factors, the factors referenced in the “Risk Factors” section of our Annual Report on Form 10 - K for the year ended December 31 , 2016 filed with the Securities and Exchange Commission on March 23 , 2017 , and in other reports filed with the SEC . In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward - looking statements contained in this presentation, they may not be predictive of results or developments in future periods . Any forward - looking statements that we make in this presentation speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this presentation, except as required by law . Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defined in Section 27 A of the Securities Act of 1933 as amended, and section 21 E of the Securities Exchange Act of 1934 , as amended . Such forward - looking statements are based upon Neuralstem , Inc . ’s management’s current expectations, estimates, beliefs, assumptions, and projections about Neuralstem’s business and industry . Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “potential,” “continue,” and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward - looking statements . In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward - looking statements . These forward - looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict . Therefore, our actual results could differ materially and adversely from those expressed in any forward - looking statements as a result of various risk factors . These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Neuralstem’s cash flow, market acceptance risks, technical development risks and other risk factors detailed in Neuralstem’s Securities and Exchange Commission filings . For links to SEC documents please visit the company’s Web site : neuralstem . com .

Key Highlights Lead Program in Phase II Development – Novel neurogenic small molecule approach – NSI - 189: Positive, randomized placebo - controlled Phase 1b in MDD – Phase II Major Depressive Disorder (MDD) • Efficacy data expected in 3Q 2017 – Montgomery - Asberg Depression Rating Scale (MADRS) primary endpoint – Cognition exploratory endpoint • Long - term durability data anticipated in 1H 2018 • Strong IP position through 2035 Cell Therapy Strategy – NSI - 566 biological activity across three indications – Partnering efforts underway for continuing development Cash balance provides runway into 2Q 2018 3

Scientific Advisory Board Comprised of World Class Psychiatric, Clinical and Regulatory Experts Dr. Maurizio Fava Harvard, MGH, Executive Vice Chair, Dept. of Psychiatry Principal Investigator: NSI - 189 Phase 2 MDD clinical trial Dr. Michael Thase Univ. of Pennsylvania, Chief. Division of Mood and Anxiety Disorders Treatment and Research Program Dr. Mark Frye Mayo Clinic, Chair, Psychiatry and Psychology Dr. John Greden Univ. of Michigan , Founder and Executive Director, Healthy System Depression Center Dr. Richard Keefe Duke Institute for Brain Sciences, Director Schizophrenia Research Group Dr. Thomas Laughren Harvard, MGH, Director, Regulatory Affairs, Former Director of Psychiatric Division, CDER, FDA 4

Management 5 Richard Daly President & Chief Executive Officer Karl Johe , Ph.D. Chief Scientific Officer Co - founder Jonathan Lloyd Jones Chief Financial Officer Thomas Hazel, Ph.D. Senior Vice President, Research 20 years as Stem Cell Discovery Program Director

Neuralstem’s proprietary technology uses regionally specific neural stem cells for the development of CNS therapies. 6 Small molecule development capability & regenerative medicine Utilizing Neural Stems Cells to Develop Novel CNS Therapies NSI - 566: Cell Therapy • Regionally specific stem cell - lines Proprietary Screening Platform NSI - 189: Lead Asset • Small molecule drug discovery

Pipeline 7 Compound Indication Preclinical Phase I Phase II Phase III Status Small Molecule: Lead Asset NSI - 189 Major Depression Disorder (MDD) Topline Results 3Q17 Supplementary Preclinical Program Angelman Syndrome Ongoing MCAO Stroke Type 1 & 2 Diabetes - related neuropathy Irradiation - induced cognition LTP Enhancement Cell Therapy (to be advanced with external funding) NSI - 566 Amyotrophic Lateral Sclerosis (ALS) BD Initiatives Chronic Spinal Cord Injury Ischemic Stroke 7

NSI - 189: A New Molecular Entity for Major Depressive Disorder

Compelling Efficacy Demonstrated To - Date – Phase Ib in Major Depressive Disorder (MDD) randomized, double - blind data • New chemical entity • Large effect size • Cognitive benefit profile • Potentially disease modifying • Excellent safety profile Phase II ongoing in MDD : randomized, double - blind placebo - controlled study MDD market opportunity – Unmet need given h igh patient turnover rate with SOC in MDD due to low efficacy and significant side effects* Preclinical Data – MOA insight: Long - term potentiation (LTP) biomarker data associated with cognitive enhancement – Orphan opportunity with Angelman Syndrome • Genetic disorder affecting the nervous system, causes developmental disabilities Strong IP position through 2035 NSI - 189 A NCE with Novel Neurogenic Mechanism of Action 9 Gaynes BN, et al; A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care setting s: preliminary findings from the STAR*D clinical trial. Gen Hosp Psychiatry. 2005 Mar - Apr;27(2):87 - 96 and Rush AJ, Fava M, et al; STAR*D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004 Feb;25(1):119 - 42.

Major Depressive Disorder Large, Unmet Medical Need: 16M US Patients TRD II - Adjunct Rx - Rx Switch - Other 4 th / 5 th - New combos TRD I - Rx Switch - Adjunct Rx - SSRI / SNRI First Line - Monotherapy - SSRI/SNRI Large patient Rx turnover due to low efficacy Low barrier to entry due to continued unmet need Adjunct/monotherapy provides large market opportunity 67% pt. failure 75% pt. failure 80% pt. failure Patients First Line TRD I TRD II 4th line + % patients in given line of therapy 33% 17% 10% 40% % patients that fail given line of therapy 67% 75% 80% N/A Source: 1. Gaynes BN, et al; A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care setting s: preliminary findings from the STAR*D clinical trial. Gen Hosp Psychiatry. 2005 Mar - Apr;27(2):87 - 96. 2. Rush AJ, Fava M, et al; STAR*D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004 Feb;25(1):119 - 42. 3 https:// www.nimh.nih.gov /health/statistics/prevalence/major - depression - among - adults.shtml . Accessed February 13, 2017 . 10 Treatment Resistant Depression Patient Journey

Cohort 1 N=8 (6 drug, 2 placebo) 40 mg QD Cohort 2 N=8 (6 drug, 2 placebo) 40 mg BID Cohort 3 N=8 (6 drug, 2 placebo) 40 mg TID Acute treatment: 28 days Drug free observational follow up: days 35, 42, 49, 56, 70, 84 NSI - 189 MDD Phase Ib trial design NSI - 189 Phase Ib double - blind, randomized, placebo - controlled, dose - escalating study assessing safety and tolerability – FDA NCE safety protocol for in - clinic dosing (28 days) – Patient criteria: At least two prior depressive episodes and currently taking or history of antidepressant medication(s) • Five day washout period – Moderate severity • A vg. MADRS 25.7, avg. age 35 11

NSI - 189 Phase 1b Results Demonstrate Trends in Efficacy & Durability Across Physician & Patient Depression Scales p=0.02 d=0.90 Study Day -20 0 20 40 60 80 100 Symptoms of Depression Questionnaire 2.0 2.2 2.4 2.6 2.8 3.0 3.2 3.4 3.6 3.8 Placebo NS-189 NS-189 1x per day NS-189 2x per day NS-189 3x per day p=0.03 d=1.10 Day 84 Day 28 Symptoms of Depression Questionnaire (SDQ) p=0.09 d=0.95 Study Day 0 20 40 60 80 100 Montgomery and Asberg Depression Rating Scale 5 10 15 20 25 30 Placebo NS-189 NS-189 1x per day NS-189 2x per day NS-189 3x per day p=0.19 d=0.84 Montgomery - Asberg Depression Rating Scale (MADRS) Day 28 All: A Phase 1B, Randomized, Double - Blind, Placebo - Controlled, Multiple - Dose Escalation Study Evaluating the Effects of NSI - 189 Phosp hate, a Neurogenic Compound, in Patients with Major Depressive Disorder (MDD) , presented June 2014, by Maurizio Fava, M.D., Karl Johe, Ph.D., Lev G. Gertsik , MD, Larry Ereshefsky , PharmD , Bettina Hoeppner , Ph.D., Martina Flynn, David Mischoulon , M.D., Ph.D., Gustavo Kinrys , M.D., and Marlene Freeman, M.D. Day 84 12 Large MADRS effect size: d=0.95 D - value, or Cohen’s effect size, is used to indicate the standardized difference between two means MADRS outcome # Definition 56% Responder 10/18 ( ≥ 50% reduction ) 50% Remission 9/18 ( ≤ 10 score) 72% Partial + Responder 13/18 (<14 score)

p=0.01 d=0.94 Study Day -20 0 20 40 60 80 100 Cognitive and Physical Functioning Questionnaire 2.0 2.5 3.0 3.5 4.0 4.5 5.0 Placebo NS-189 NS-189 1x per day NS-189 2x per day NS-189 3x per day p<0.01 d=1.20 Day 28 Day 84 NSI - 189 MDD Phase Ib clinical results All: A Phase 1B, Randomized, Double - Blind, Placebo - Controlled, Multiple - Dose Escalation Study Evaluating the Effects of NSI - 189 Phosp hate, a Neurogenic Compound, in Patients with Major Depressive Disorder (MDD) , presented June 2014, by Maurizio Fava, M.D., Karl Johe, Ph.D., Lev G. Gertsik , MD, Larry Ereshefsky , PharmD , Bettina Hoeppner , Ph.D., Martina Flynn, David Mischoulon , M.D., Ph.D., Gustavo Kinrys , M.D., and Marlene Freeman, M.D. Cognitive and Physical Functioning Questionnaire (CPFQ) 13 Demonstrate trends in improved cognition in patient reported outcomes Large effect size (d=0.94)

NSI - 189: Excellent Safety Profile with No Serious SAEs 14

NSI - 189: Ongoing Phase 2 MDD Trial, Topline Results Expected 3Q 2017 15 Study Objectives – Primary: Montgomery - Asberg Depression Rating Scale (MADRS ) – Secondary*: SDQ, HAMD17, CGI - S, CPFQ, SFI – Exploratory: Cogscreen Battery, Cogstate Brief Battery Innovative Study Design – Randomized, double blind, 3 cohorts (n=220): 40mg BID, 40mg QD, & placebo – 12 - week study, additional 6 month follow - up study – Fewer, quality MDD trial sites (n=12) – Prescreen process to manage placebo risk – SAFER Interview: confirmatory, i ndependent, remote MADRS diagnosis by MGH – Potential registration study if successful in either active arm • Power: >80%, 2 - sided p≤ 0.05; d=0.5 Principal Investigator: Maurizio Fava, M.D. Slater Family Professor of Psychiatry at Harvard Medical School, Massachusetts General Hospital *Symptoms of Depression Questionnaire (SDQ) Hamilton Depression Rating Scale 17 - items (HAM 17) Clinical Global Impressions Scale (CGI - S) Cognitive and Physical Functioning Questionnaire (CPFQ) Sexual Functional Index (SFI)

NSI - 189: Preclinical Data Support Characteristics of Neurogenesis, Cognitive Enhancement & Durability 16

Preclinical Overview 17 • Treatment of a rat model for ischemic stroke shows a durable effect in promoting behavioral recovery that corresponds with increased neurogenesis • Type 1 & 2 diabetic neuropathy reversal and prevention • Prevention of cognitive deficit in irradiated mice • MOA: Enhances long - term potentiation (LTP) in normal mice • Restores LTP in Angelman Syndrome mouse Preclinical data suggests a new paradigm for reversing damage caused by disease/injury

Orphan Opportunity in Angelman Syndrome 0 50 100 150 200 250 -10 -5 0 5 10 15 20 25 30 35 40 AS WT-vehicle AS-NSI189 EPSP slope (% of baseline) Time (min) NSI - 189 restores LTP in Angelman Syndrome Mice Confirmatory model in a genetic disease By courtesy of Yan Liu 1 , Xiaoning Bi 1 , Michel Baudry 1 Western University of Health Sciences, Pomona, CA 91766 18

NSI - 189 Enhances LTP Magnitude 19 TBS after 2.5 h incubation 0 50 100 150 200 250 300 350 -10 -5 0 5 10 15 20 25 30 35 40 WT-Vehicle WT-NSI189 Vehicle EPSP slope (% of baseline) TBS after 3.5 h incubation 0 50 100 150 200 250 300 350 -10 -5 0 5 10 15 20 25 30 35 40 WT-Vehicle WT-NSI189 Vehicle Time (min) • Enhances short - term and long - term potentiation in normal mice (n=8 slices) • Increases with exposure time and concentration (10μM) (10μM) By courtesy of Yan Liu 1 , Xiaoning Bi 1 , Michel Baudry 1 Western University of Health Sciences, Pomona, CA 91766 For mechanistic studies: cognition = memory LTP is a cellular biomarker of memory

Stem Cell Development Efforts & Strategy

Cell Therapy : Biological Activity A cross T hree I ndications 21 – ALS Phase 1 & 2 follow - up evaluation – Phase I stroke completed dosing all 9 patients and currently evaluating safety – cSCI is currently evaluating 4 Phase 1 thoracic patients; Phase 1 trial recruiting additional ( Group B) 4 cervical patients Indication Preclinical Phase I Phase II Phase III Status Cell Therapy (to be advanced with external funding) NSI - 566 Amyotrophic Lateral Sclerosis (ALS) Phase 2a completed Chronic Spinal Cord Injury Phase 1 follow - up Ischemic Stroke Phase 1 follow - up

Lead Product: NSI - 566 Chemically defined culture system – No serum, no feeder cells, no particulates, no unknown raw material – Fully tested for potential pathogens; validated SOPs Efficient expansion – Multi - tiered cell banks for maximum efficiency – Scalable expansion – Relatively small infrastructure Stable phenotype – Normal karyotype of 44 + XY chromosomes – Reproducible bank release characteristics (identity, purity, potency) – Predictable in vivo differentiation 22

NSI - 566: Preliminary Data in 3 Indications PROGRAM OVERVIEW - Transplantation into spinal cord of ALS - Phase 1 & Phase 2a dose - escalation, safety studies completed - 30 subjects with 2 - 6 years of safety data KEY TAKEAWAYS - Procedure and treatment is well - tolerated - L ong - term cell graft survival (2.5 years) in autopsy MARKET CONSIDERATIONS - Orphan condition - Rapid accelerating disease - Limited treatments PROGRAM OVERVIEW - USCD funded - Phase I cSCI Group A 4 Thoracic AISA - A complete spinal cord injury (dosing completed) - Phase I cSCI Group B 4 Cervical AISA - A complete spinal cord injury (recruiting) KEY TAKEAWAYS - Stem cell treatment was safe and well - tolerated - No serious adverse events - Self - reported ability to contact some muscles below the level of injury in of of the four subjects treated was confirmed via clinical and electrophysiological follow - up examinations MARKET CONSIDERATIONS - 270,000 Americans live with cSCI - 11,000 new injuries per year - No treatment options ALS Chronic Spinal Cord Injury Ischemic Stroke PROGRAM OVERVIEW - Phase 1 open - label, dose - escalation, feasibility & safety study for the treatment of paralysis from chronic motor stroke - Patient profile: 9 subjects 3 - 24 months post stroke with stable hemi - paralysis KEY TAKEAWAYS - Treatment well - tolerated - Innovative brain injection cannula MARKET CONSIDERATIONS - 15mm people suffer stroke worldwide - Estimated 25% of ischemic stroke 23

Continued Execution of New Corporate & Clinical Development Strategy 24 2016 x Jan : Refocused clinical development strategy on NSI - 189 x Feb : Rich Daly joins as the new CEO x May : Initiation of Phase 2 MDD study for NSI - 189 x $9mn institutional capital raise x Corporate reorganization to align with updated strategy x Jun : Rich Daly appointed Chairman, Board of Directors x Business development/partnering efforts in cell therapy begin x Sept : 50% enrollment in Phase 2 MDD trial achieved ahead of schedule x Dec : Closing of Tianjin Pharmaceutical Group $20mn strategic investment 2017 x Jan : 13 - 1 reverse split, regaining Nasdaq compliance x Feb : Last patient enrolled NSI - 189 Phase 2 MDD study □ 3Q : Phase 2 MDD MADRS results expected 4 months ahead of schedule 2018 □ 1H : Phase 2 MDD 6 month durability results

Key Highlights Lead Program in Phase II Development – Novel neurogenic small molecule approach – NSI - 189: Positive, randomized placebo - controlled Phase 1b in MDD – Phase II Major Depressive Disorder (MDD) • Efficacy data expected in 3Q 2017 – Montgomery - Asberg Depression Rating Scale (MADRS) primary endpoint – Cognition exploratory endpoint • Long - term durability data anticipated in 1H 2018 • Strong IP position through 2035 Cell Therapy Strategy – NSI - 566 biological activity across three indications – Partnering efforts underway for continuing development Cash balance provides runway into 2Q 2018 25